Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17.

Int J Mol Sci

Tri-Institutional MD/PhD Program, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine, Rockefeller University, New York, NY 10021, USA.

Published: February 2021

Notch signaling is critical for controlling a variety of cell fate decisions during metazoan development and homeostasis. This unique, highly conserved signaling pathway relies on cell-to-cell contact, which triggers the proteolytic release of the cytoplasmic domain of the membrane-anchored transcription factor Notch from the membrane. A disintegrin and metalloproteinase (ADAM) proteins are crucial for Notch activation by processing its S2 site. While ADAM10 cleaves Notch1 under physiological, ligand-dependent conditions, ADAM17 mainly cleaves Notch1 under ligand-independent conditions. However, the mechanism(s) that regulate the distinct contributions of these ADAMs in Notch processing remain unclear. Using cell-based assays in mouse embryonic fibroblasts (mEFs) lacking ADAM10 and/or ADAM17, we aimed to clarify what determines the relative contributions of ADAM10 and ADAM17 to ligand-dependent or ligand-independent Notch processing. We found that EDTA-stimulated ADAM17-dependent Notch1 processing is rapid and requires the ADAM17-regulators iRhom1 and iRhom2, whereas the Delta-like 4-induced ligand-dependent Notch1 processing is slower and requires ADAM10. The selectivity of ADAM17 for EDTA-induced Notch1 processing can most likely be explained by a preference for ADAM17 over ADAM10 for the Notch1 cleavage site and by the stronger inhibition of ADAM10 by EDTA. The physiological ADAM10-dependent processing of Notch1 cannot be compensated for by ADAM17 in mEFs, or by other ADAMs shown here to be able to cleave the Notch1 cleavage site, such as ADAMs9, 12, and 19. Collectively, these results provide new insights into the mechanisms underlying the substrate selectivity of ADAM10 and ADAM17 towards Notch1.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918056PMC
http://dx.doi.org/10.3390/ijms22041846DOI Listing

Publication Analysis

Top Keywords

adam10 adam17
12
notch1 processing
12
notch1
10
processing
8
adam10
8
adam17
8
cleaves notch1
8
notch processing
8
notch1 cleavage
8
cleavage site
8

Similar Publications

Understanding cell fate regulation in the liver is necessary to advance cell therapies for hepatic disease. Liver progenitor cells (LPC) contribute to tissue regeneration after severe hepatic injury yet signals instructing progenitor cell dynamics and fate are largely unknown. The Tissue Inhibitor of Metalloproteinases, TIMP1 and TIMP3 control the sheddases ADAM10 and ADAM17, key for NOTCH activation.

View Article and Find Full Text PDF

Background: In this study, we investigate the impact of a multi-targeted therapeutic approach that includes camptothecin (CPT), a potent chemotherapeutic topoisomerase inhibitor; metformin (Met), a metabolic modulator with emerging anti-tumor effects; and GW280264X, an inhibitor of ADAM 10/ADAM 17 enzymes, which are associated with tumor invasion and immune response. The study aims to assess the combined effects of these agents in enhancing CD8 T cell-mediated anti-tumor immunity and suppressing cancer cell growth in triple-negative breast cancer (TNBC) models, both in vitro and in vivo.

Methods: Cell viability was performed on the 4 T1 human TNBC cell line.

View Article and Find Full Text PDF
Article Synopsis
  • Ipriflavone (IPRI) is used to prevent postmenopausal bone loss and offers antioxidant and cognitive benefits, but it has low bioavailability due to poor solubility.
  • In this study, IPRI was formulated into targeted poly-lactic-co-glycolic acid (PLGA) nanoparticles with Tet-1 peptide to enhance its therapeutic effects in a rat model of Alzheimer's disease (AD), exacerbated by streptozotocin (STZ) injections.
  • Results showed that IPRI nanoparticles were more effective than free IPRI in reducing cognitive dysfunction, oxidative stress, and neurodegenerative changes, leading to improved neuronal cell viability and reduced Alzheimer's
View Article and Find Full Text PDF

VE-cadherin shedding in vitro and in patients with aortic aneurysm and dissection.

Sci Rep

November 2024

Clinic for Vascular and Endovascular Surgery, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.

VE-cadherin (VEC) is a major endothelial adhesion protein, which controls vascular homeostasis. During vascular diseases, VEC can be shed from the endothelial surface by proteases like ADAM10/17, which cleave the extracellular domain of VEC in response to inflammatory cytokines like TNF-α. The resulting, soluble fragments (sVEC) are discussed as a potential marker for endothelial barrier breakdown.

View Article and Find Full Text PDF
Article Synopsis
  • * One selective antibody fragment, C12, was developed into a full IgG and was shown to bind effectively to ADAM17, preventing the activation of cancer cell pathways by inhibiting EGFR phosphorylation.
  • * C12 demonstrated anti-tumor effects by reducing the viability of various EGFR-expressing cancer cells and inhibiting tumor growth in an ovarian cancer model, with imaging confirming its presence at tumor sites.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!